<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072579</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU-23102</org_study_id>
    <secondary_id>CDR0000340983</secondary_id>
    <secondary_id>BRLX-02153</secondary_id>
    <secondary_id>NCI-7350</secondary_id>
    <nct_id>NCT00072579</nct_id>
  </id_info>
  <brief_title>Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment</brief_title>
  <official_title>Phase II Study of GM-CSF in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Who Are Not in Complete Cytogenetic Remission After Initial Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of&#xD;
      immune cells found in bone marrow or peripheral blood and may bring about complete remission&#xD;
      in patients who have chronic phase chronic myelogenous leukemia.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying sargramostim to see how well it works in treating&#xD;
      patients with chronic phase chronic myelogenous leukemia that is not in complete cytogenetic&#xD;
      remission after initial treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy and safety of sargramostim (GM-CSF) by cytogenetic examination of&#xD;
           the bone marrow in patients with chronic phase chronic myelogenous leukemia who are not&#xD;
           in complete cytogenetic remission after initial therapy.&#xD;
&#xD;
      OUTLINE: Patients receive sargramostim (GM-CSF) subcutaneously daily for 3 months in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients achieving no response&#xD;
      receive GM-CSF for an additional 3 months. Patients failing to achieve a partial response or&#xD;
      better after the second course of GM-CSF are removed from the study. Patients achieving a&#xD;
      partial response after the first or second course of GM-CSF continue to receive GM-CSF for an&#xD;
      additional 9 months. Patients are then re-evaluated. Patients achieving a complete cytologic&#xD;
      response at 9 months then receive GM-CSF 3 times weekly in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytogenetic response (complete and partial)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by the Expanded Common Toxicity Criteria v2.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed chronic phase chronic myelogenous leukemia (CML)&#xD;
&#xD;
               -  Presence of t(9;22)(q34;q11) with at least 20 cells examined in metaphase by&#xD;
                  cytogenetic examination of the bone marrow&#xD;
&#xD;
          -  Complete hematologic remission during prior therapy* as seen on 2 separate blood count&#xD;
             analyses, defined by the following:&#xD;
&#xD;
               -  WBC no greater than 10,000/mm^3 AND platelet count no greater than 450,000/mm^3&#xD;
&#xD;
               -  Disappearance of all signs and symptoms of disease, including palpable&#xD;
                  splenomegaly&#xD;
&#xD;
               -  Normal differential counts (i.e., absence of blasts, promyelocytes, myelocytes,&#xD;
                  and metamyelocytes) NOTE: *Continuation of therapy that led to complete&#xD;
                  hematologic remission is required during study participation&#xD;
&#xD;
          -  Persistent cytogenetic disease despite 12 months of prior imatinib mesylate therapy,&#xD;
             which may have included a trial dose-escalation OR intolerant of imatinib mesylate at&#xD;
             a dose greater than 400 mg/day&#xD;
&#xD;
          -  Not in complete cytogenetic remission within 30 days of study entry&#xD;
&#xD;
               -  Persistent Philadelphia chromosome by bone marrow exam&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled active infective&#xD;
&#xD;
          -  No serious medical or psychiatric illness that would prevent giving informed consent&#xD;
             or limit survival to less than 6 months&#xD;
&#xD;
          -  No other malignancy not in remission except curatively treated basal cell skin cancer&#xD;
             or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior sargramostim (GM-CSF) allowed&#xD;
&#xD;
          -  Prior interferon alfa for CML allowed&#xD;
&#xD;
          -  No prior stem cell transplantation&#xD;
&#xD;
          -  Concurrent interferon alfa* for CML allowed NOTE: *No dose increase during study&#xD;
             participation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior imatinib mesylate for CML allowed&#xD;
&#xD;
          -  No other concurrent medication for CML&#xD;
&#xD;
          -  Concurrent imatinib mesylate* for CML allowed NOTE: *No dose increase during study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Istvan Molnar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bayard L. Powell, MD</last_name>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Western Regional, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Bay Area Tumor Institute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-3305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Radiation Oncology Center at Rome</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Cancer Institute, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hugh Chatham Memorial Hospital</name>
      <address>
        <city>Elkin</city>
        <state>North Carolina</state>
        <zip>28621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534-9479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brody School of Medicine at East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas - Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2003</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

